Collective expert perspectives on the use of safinamide as adjunctive therapy for Parkinson’s disease in Japan: Online-based Delphi approach
Objective: To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in…Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.
Objective: Investigation on Parkinson's patients with therapy-resistant tremor usingapomorphine-pen injection for alleviation of resting tremor. Background: In Parkinson’s disease one of the major disturbing symptoms…Neuroprotective effect of Boswellia dalzielii extracts in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
Objective: To evaluate the possible protective effects of Boswellia dalzielii in animal model of Parkinson Disease (PD) induced by 6-hydroxydopamine (6-OHDA) injection in the striatum…Diagnosed and Drug-Treated Prevalence of Essential Tremor in Adult Patients: Retrospective Analyses of Two US Healthcare Claims Databases
Objective: Estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in the adult population using 2 US healthcare claims databases. Background: ET is a…Factors related to the antidepressant effect of safinamide in Parkinson’s disease. A post-hoc analysis of SADNESS-PD study
Objective: To assess the role of different factors in the antidepressant effect of safinamide in Parkinson’s disease (PD) Background: SADNESS-PD was a real-life, multicenter, retrospective…Comparing duodenal levodopa infusion based on length of treatment in advanced Parkinson’s.
Objective: In this study we seek to compare characteristics and complications of patients suffering from advanced Parkinson's treated with duodenal levodopa infusion. Background: Motor fluctuations…Beta-agonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies
Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of beta-agonist and the risk of PD.…Effect of the mGlu2/3 orthosteric agonist LY-404,039 on dyskinesia, psychosis-like behaviours, and parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effect of LY-404,039 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson’s disease (PD). Background:…Chronic administration of bitopertin, a GlyT1 inhibitor, in the dyskinetic 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To evaluate if, upon chronic administration, tolerance to the anti-dyskinetic effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin, would develop, in the 6-hydroxydopamine…Systematic Literature Review of Key Outcomes Used to Assess Adjunctive Treatments for Parkinson’s Disease
Objective: Understand key efficacy outcomes used to assess adjunctive treatments to carbidopa/levodopa (CD/LD) for Parkinson’s disease (PD). Background: CD/LD is widely considered the most effective…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 34
- Next Page »